Monoclonal Antibody to Inhibit Spike Glycoprotein for Coronavirus Disease 2019 (COVID-19) is under clinical development by Jecho Biopharmaceuticals and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Monoclonal Antibody to Inhibit Spike Glycoprotein for Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal Antibody to Inhibit Spike Glycoprotein for Coronavirus Disease 2019 (COVID-19) overview
Monoclonal antibody (COVID-19 No.1) is under development for the treatment of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It acts by targeting spike protein.
Jecho Biopharmaceuticals overview
Jecho Biopharmaceuticals is a biopharmaceutical company that focuses on the research, development, production, and sales of biopharmaceuticals. Its main activities include the development of monoclonal antibodies, recombinant proteins, oncolytic viruses, immunotoxins, and vaccines. The company focuses on cooperative biopharmaceutical research and development; and commissioned production, offering complete solutions through cell line screening and mass production. Jecho Biopharmaceuticals investigates JL14001, a novel recombinant protein to treat anemia caused by chemotherapy and chronic kidney diseases; JL14002 biosimilar against age related macular degeneration and other ophthalmic diseases; JL15003 for glioma; JL17001, JL18004 and CDMO 001 for the treatment of tumor. The company is evaluating JL18008 against lymphocytopenia and tumor immunotherapy; and CDMO 002 immunotoxin to treat hairy cell leukemia. The company provides competitive products and value-added services to global customers, addressing needs in fields such as ophthalmology, immune system deficiencies, tumors, and anemia. Jecho Biopharmaceuticals is headquartered in Tianjin, China.
For a complete picture of Monoclonal Antibody to Inhibit Spike Glycoprotein for Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.